Cutaneous T-cell lymphoma is a group of non-Hodgkin lymphomas characterized by malignant T cells primarily involving the skin. It often presents with patch, plaque, or tumor skin lesions and includes subtypes such as mycosis fungoides and Sezary syndrome. Disease course is variable, and advanced stages may involve blood, lymph nodes, or viscera.
A phase 1 trial shows denileukin diftitox administered before CAR-T therapy has a favorable safety profile and encouraging efficacy in high-risk DLBCL patients, with an 86% overall response rate and 77% one-year progression-free survival. The treatment demonstrated consistent regulatory T-cell depletion, supporting its immunomodulatory mechanism. Larger controlled studies are needed to confirm these preliminary findings.
The global oncology market is projected to grow from $280 billion in 2026 to $748 billion by 2035 at 11.54% CAGR, driven by rising cancer incidence, precision medicine expansion, and strong immunotherapy pipelines across multiple tumor types.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07356245 |
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma |
RECRUITING | PHASE2 |
| NCT07047885 |
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL) |
RECRUITING | PHASE1 |
| NCT06860880 |
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program |
RECRUITING | NA |
| NCT06716658 |
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas |
RECRUITING | PHASE2 |
| NCT06665490 |
Pilot Study to Characterize the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of CLn® Skin Care Body Wash |
ENROLLING_BY_INVITATION | |
| NCT06651203 |
Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study |
NOT_YET_RECRUITING | |
| NCT06588868 |
Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma |
RECRUITING | |
| NCT06470451 |
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL |
RECRUITING | PHASE3 |
| NCT06436677 |
A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma |
RECRUITING | |
| NCT06385522 |
A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System |
NOT_YET_RECRUITING | PHASE1 |
